NCT05283512View on ClinicalTrials.gov

Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease

NARecruitingINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

April 20, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Contrast-induced NephropathyKidney InjuryKidney Failure, ChronicRisk Reduction
Interventions
OTHER

Preventive treatment with IV-hydration

IV hydration with isotonic 0.9% NaCl

OTHER

Preventive treatment with oral hydration

Oral hydration with regular bottled water

Trial Locations (1)

5000

RECRUITING

Department of Cardiology, Odense C

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Department of Nephrology, Odense University Hospital

UNKNOWN

collaborator

Department of Clinical Genetics, Odense University Hospital

UNKNOWN

collaborator

The A.P. Moller Foundation

UNKNOWN

collaborator

The Research Counsil of Odense University Hospital

UNKNOWN

collaborator

Copenhagen University's Research Foundation for Medical Students

UNKNOWN

collaborator

Helen and Ejnar Bjørnow's Foundation

UNKNOWN

collaborator

Novo Nordisk A/S

INDUSTRY

collaborator

Sophus Jacobsen and Astrid Jacobsen's Foundation

UNKNOWN

collaborator

Region of Southern Denmark

OTHER

lead

Odense University Hospital

OTHER

NCT05283512 - Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease | Biotech Hunter | Biotech Hunter